San Francisco Bay Area biotech stories.
Tuesday, July 24, 2012
Genentech's Lucentis restores diabetic vision loss, FDA says
Inc.'s eye drug Lucentis improved the vision of people with a type of blindness associated with diabetes, drug regulators said in a report Tuesday
according to the news agency Bloomberg
. The report came in advance of a Food and Drug Administration advisory committee meeting Thursday in which Genentech hopes to expand the use of Lucentis from wet age-related macular degeneration to patients with diabetic macular edema.
Share to Twitter
Share to Facebook
Share to Pinterest
Post a Comment
Post Comments (Atom)